Breaking News

Samsung Life Science Fund Invests in BrickBio

Samsung affiliates will work with BrickBio to evaluate, manufacture, and develop therapies using BrickBio's protein engineering technology.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Samsung Life Science Fund, created jointly between Samsung Biologics, Samsung Bioepis, and Samsung C&T, and managed by Samsung Ventures, and BrickBio, Inc. announced Samsung’s investment in BrickBio, a preclinical-stage biopharmaceutical company focused on developing precision biologics using an expanded genetic code.   Samsung affiliates will work with BrickBio to evaluate, manufacture, and develop advanced molecules and therapies using BrickBio’s protein engineering technolog...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters